Interestingly, treatment of tumor cells with EGFR tyrosine kinase inhibitors (EGFR-TKI) was shown to upregulate HLA-DR expression on tumor cells and enhance recognition by EGFR875-889-specific CD4 T cells. Here, CD4 is linked to neoplasm.